Clinical importance of anti-Ro52 antibody in polymyositis and dermatomyositis

Author:

Sugita Toshiki1,Tsuboi Hiroto1ORCID,Sugita Naoki1,Akiyoshi Rai1,Kuroda Yuki1,Kawashima Akira1,Kawashima Fumina1,Tabuchi Daiki1,Honda Fumika1,Ohyama Ayako1,Abe Saori1,Kitada Ayako1,Asashima Hiromitsu1,Miki Haruka1,Hagiwara Shinya1,Kondo Yuya1,Matsumoto Isao1

Affiliation:

1. Department of Rheumatology, Institute of Medicine, University of Tsukuba , Ibaraki, Japan

Abstract

ABSTRACT Objectives To clarify the clinical features of anti-Ro52 antibody (Ab)-positive polymyositis (PM)/dermatomyositis (DM). Methods We retrospectively examined the clinical features and status of anti-Ro52 Abs in patients with PM/DM admitted to the University of Tsukuba Hospital between January 2019 and February 2023. We compared the anti-Ro52 Ab-positive and anti-Ro52 Ab-negative groups. Results A total of 40 patients were selected and analysed. Twenty-three cases were PM, and 17 cases were DM (including six clinically amyopathic DM). Twenty-two cases were positive for anti-Ro52 Ab, 14 for anti-ARS Ab, and 6 for anti-MDA5 Ab. Interstitial lung disease was detected in 29 cases, nine of which were rapidly progressive. Glucocorticoid-resistant cardiomyopathy was detected in six cases. Of the 22 anti-Ro52 Ab-positive cases, only 3 were single-positive and the remaining 19 cases simultaneously had other autoantibodies. Comparing the anti-Ro52 Ab-positive and anti-Ro52 Ab-negative groups, the frequencies of anti-ARS Ab positivity (63.6% vs. 0%), interstitial lung disease (95.5% vs. 44.4%), glucocorticoid-resistant cardiomyopathy (27.3% vs. 0%), concomitant use of immunosuppressants (95.5% vs. 55.6%), and levels of C-reactive protein were significantly higher in the anti-Ro52 Ab-positive group (P < .05). Conclusions Anti-Ro52 Abs were frequently positive in PM/DM, and may be useful as a severity marker.

Publisher

Oxford University Press (OUP)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3